"A positive trend in overall survival" had been seen in a trial, with an interim analysis demonstrating a 29% reduction in the risk of death for Nubeqa.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.